← Eichor
Condition: Genetic Mutation Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Genetic Mutation

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer
Phase 2 · 2 location(s) · BeBetter Med Inc · NCT06706713Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MY
Phase 1/Phase 2 · 10 location(s) · Tenaya Therapeutics · NCT05836259Phase I Study of HSK40118 in NSCLC Patients With EGFR Mutation
Phase 1 · 12 location(s) · Haisco Pharmaceutical Group Co., Ltd. · NCT06050980A Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CITY-FXI in H
Phase 1 · 1 location(s) · City Therapeutics · NCT07430397Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations
Phase 1 · 3 location(s) · Adlai Nortye Biopharma Co., Ltd. · NCT07252479A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7, MUSK, AGRN,
Phase N/A · 32 location(s) · argenx · NCT06078553Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
Phase 1/Phase 2 · 10 location(s) · SynDevRx, Inc. · NCT05455619Ivosidenib in Locally Advanced or Metastatic Cholangiocarcinoma With IDH1 R132 Mutation After at Least One Prior Systemi
Phase N/A · 13 location(s) · iOMEDICO AG · NCT06607302Natural History of Photoreceptor Degeneration in USH1B: Clinical Parameters and Validation of Functional Vision Tests in
Phase N/A · 1 location(s) · Centre Hospitalier National d'Ophtalmologie des Quinze-Vingt · NCT07278843A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients
Phase 2 · 2 location(s) · Mehmet Akce · NCT06728410A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mut
Phase 3 · 5 location(s) · Astellas Pharma Global Development, Inc. · NCT07566052DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study
Phase N/A · 2 location(s) · National Cancer Institute (NCI) · NCT01247597EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations
NA · 6 location(s) · Dana-Farber Cancer Institute · NCT06716580Development of a cfDNA 5mC/5hmC-based Biomarker Panel to Predict Targeted Therapy Efficacy in mCRC
Phase N/A · 1 location(s) · City of Hope Medical Center · NCT07224841A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAP
Phase 1/Phase 2 · 14 location(s) · D3 Bio (Wuxi) Co., Ltd · NCT05886920Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor
Phase 2 · 84 location(s) · Merck Sharp & Dohme LLC · NCT04924075The Natural History of TRPV4 Neuropathy
Phase N/A · 1 location(s) · Johns Hopkins University · NCT05600764Videocapsule Endoscopy in Lynch Syndrome
NA · 1 location(s) · San Raffaele University · NCT05704010A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients
Phase 1 · 41 location(s) · Genentech, Inc. · NCT06619587Open-label Study of SKY-GJB2 in Pediatric Subjects With GJB2-mediated Hearing Loss
Phase 1/Phase 2 · 3 location(s) · Skylark Bio Inc. · NCT07627971Chronic CED of TPT for Recurrent Malignant Glioma
Phase 1 · 1 location(s) · Jeffrey N. Bruce · NCT06666712First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Parti
Phase 1/Phase 2 · 65 location(s) · Eli Lilly and Company · NCT05768139Alectinib Followed by Concomitant Consolidation Radiation Therapy in Advanced NSCLC With ALK-rearrangement (A-SAB)
NA · 1 location(s) · Karolinska University Hospital · NCT05724004A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Mye
Phase 1 · 29 location(s) · Incyte Corporation · NCT05936359Lung Cancer Screening of Family Members of Patients With Mutation-Driven Lung Cancer
NA · 1 location(s) · University of California, Irvine · NCT07062172PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas
Phase 1 · 5 location(s) · Pasithea Therapeutics Corp. · NCT06961565Toripalimab（JS001） as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors
Phase 2 · 4 location(s) · Sun Yat-sen University · NCT03810339Characterization of a Functional Test for Mediterranean Family Fever Screening - 2
Phase N/A · 8 location(s) · Hospices Civils de Lyon · NCT04478409A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KR
Phase 3 · 419 location(s) · Eli Lilly and Company · NCT06119581Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Phase 1/Phase 2 · 93 location(s) · Revolution Medicines, Inc. · NCT06162221
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.